{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:44:15Z","timestamp":1790876655756,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Innovative Medicines Initiative Joint"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ijpharm.2016.10.018","type":"journal-article","created":{"date-parts":[[2016,10,15]],"date-time":"2016-10-15T10:38:50Z","timestamp":1476527930000},"page":"352-358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT"],"prefix":"10.1016","volume":"515","author":[{"given":"Alexandros","family":"Kourentas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vertzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Symillides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Hens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Augustijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Reppas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2016.10.018_bib0005","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejps.2013.08.027","article-title":"A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption","volume":"57","author":"Augustijns","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0010","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ejpb.2014.08.011","article-title":"Prediction of oral absorption of cinnarizine\u2013a highly supersaturating poorly soluble weak base with borderline permeability","volume":"88","author":"Berlin","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejpb.2015.03.031","article-title":"Advances and challenges in PBPK modeling-Analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base","volume":"93","author":"Berlin","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0020","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1002\/jps.22154","article-title":"Drug supersaturation in simulated and human intestinal fluids representing different nutritional states","volume":"99","author":"Bevernage","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0025","article-title":"Gastrointestinal behavior of supersaturating drug delivery systems for itraconazole in humans","author":"Brouwers","year":"2015","journal-title":"AAPS Annual Meeting & Exposition. Florida, USA, 25\u201329 October 2015"},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0030","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0035","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jps.20495","article-title":"Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model","volume":"95","author":"Carino","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0040","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1469-0691.2011.03732.x","article-title":"HPLC\/UV or bioassay: two valid methods for posaconazole quantification in human serum samples","volume":"18","author":"Cendejas-Bueno","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0045","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0050","unstructured":"European Medicines Agency, Summary of product characteristics, Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000610\/WC500037784.pdf (accessed 13.06.16)."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0055","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1023\/A:1011910801212","article-title":"Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs","volume":"15","author":"Galia","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejps.2014.07.008","article-title":"Gastrointestinal transfer: in vivo evaluation and implementation in in vitro and in silico predictive tools","volume":"63","author":"Hens","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0065","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/jps.24690","article-title":"Supersaturation and precipitation of posaconazole upon entry in the upper small intestine in humans","volume":"105","author":"Hens","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0070","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s11095-008-9569-4","article-title":"Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update","volume":"25","author":"Jantratid","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejps.2014.10.019","article-title":"Statistical investigation of simulated intestinal fluid composition on the equilibrium solubility of biopharmaceutics classification system class II drugs","volume":"67","author":"Khadra","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1211\/0022357022511","article-title":"Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine","volume":"56","author":"Kostewicz","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0085","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejps.2013.08.024","article-title":"In vitro models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejps.2015.11.012","article-title":"An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: design, implementation, and evaluation","volume":"80","author":"Kourentas","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0095","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.xphs.2016.04.037","article-title":"Evaluation of the impact of excipients and an albendazole salt on albendazole concentrations in upper small intestine using an in vitro biorelevant gastrointestinal transfer (BioGIT) system","volume":"105","author":"Kourentas","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0100","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1021\/acs.molpharmaceut.6b00297","article-title":"Effect of seed particles on precipitation of weak base drugs in physiological intestinal conditions","volume":"13","author":"Koyama","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0105","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2147\/IJN.S57565","article-title":"Formulation and delivery of itraconazole to the brain using a nanolipid carrier system","volume":"9","author":"Lim","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0110","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejpb.2015.03.009","article-title":"In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: choosing the appropriate test media","volume":"93","author":"Markopoulos","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0115","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.xphs.2016.02.020","article-title":"The evaluation of In vitro drug dissolution of commercially available oral dosage forms for itraconazole in gastrointestinal simulator with biorelevant media","volume":"105","author":"Matsui","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0120","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1021\/mp500196f","article-title":"Effect of surfactants, gastric emptying, and dosage form on supersaturation of dipyridamole in an in vitro model simulating the stomach and duodenum","volume":"11","author":"Mitra","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0125","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/jps.10126","article-title":"Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7","volume":"91","author":"Peeters","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0130","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1007\/s11095-012-0844-z","article-title":"An in vitro methodology for forecasting luminal concentrations and precipitation of highly permeable lipophilic weak bases in the fasted upper small intestine","volume":"29","author":"Psachoulias","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0135","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4172\/jbb.1000162","article-title":"Dissolution effect of gastric and intestinal pH for BCS class II drug, pioglitazone: new in vitro dissolution system to predict in vivo dissolution","volume":"5","author":"Tsume","year":"2013","journal-title":"J. Bioequiv. Availab."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0140","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2015.05.013","article-title":"In vitro dissolution methodology, mini-gastrointestinal simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib","volume":"76","author":"Tsume","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0145","series-title":"AAPS Annual Meeting","article-title":"Influence of fasted state gastric motor function on intragastric drug distribution in man","author":"Van Den Abeele","year":"2016"},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0150","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/11592630-000000000-00000","article-title":"Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations","volume":"50","author":"Walravens","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0155","unstructured":"electronic Medicines Compendium, List of excipients, Available at: https:\/\/www.medicines.org.uk\/EMC\/medicine\/7395\/SPC\/Sporanox+Capsules\/#EXCIPIENTS (accessed 13.06.16)."},{"key":"10.1016\/j.ijpharm.2016.10.018_bib0160","unstructured":"electronic Medicines Compendium, List of excipients, Available at: https:\/\/www.medicines.org.uk\/emc\/medicine\/7514\/SPC\/Sporanox+10+mg+ml+Oral+Solution\/#EXCIPIENTS (accessed 13.06.16)."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316309528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316309528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T17:23:06Z","timestamp":1536340986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517316309528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":32,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0378517316309528"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.10.018","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}